Unique update around the phase 2 component of the trial to be released in the very near future will i suspect align the 42x drug candidate with the FDAs' risk/benefit drug approval analysis of 49/51 which may well allow
special access to the drug for those applicants suffering at the critical end of the OSA spectrum with high risk co-morbidities...that would be truly unique in the OSA space and move 42X into a commercial market space where there is currently zero FDA approved medications
Further, should the 2/3 interims match the phase 2 at 50+ % AHI endpoint outcome improvement and better than 80% improvement for 25% of the 2/3 500+ participant trial cohort then this drug candidate will most surely be snapped up by Big Pharma and render obsolete all current CPAP applications in the market along with the revenues they currently generate.
this drug candidate is a game changer globally - no question
the numbers are correct
